DrugBank ID: db00159
DrugCentral: icosapent
Synonymous :(5z,8z,11z,14z,17z)-5,8,11,14,17-eicosapentaenoic acid | (5z,8z,11z,14z,17z)-eicosapentaenoate | (5z,8z,11z,14z,17z)-eicosapentaenoic acid | (5z,8z,11z,14z,17z)-icosapentaenoic acid | (all-z)-5,8,11,14,17-eicosapentaenoic acid | 5,8,11,14,17-eicosapentaenoic acid | 5,8,11,14,17-icosapentaenoic acid | all-cis-5,8,11,14,17-eicosapentaenoic acid | all-cis-5,8,11,14,17-icosapentaenoic acid | all-cis-icosa-5,8,11,14,17-pentaenoic acid | cis-5,8,11,14,17-eicosapentaenoic acid | cis-5,8,11,14,17-epa | cis-delta(5,8,11,14,17)-eicosapentaenoic acid | eicosapentaenoic acid | epa | icosapent | icosapentaenoic acid | icosapento | icosapentum | timnodonic acid

Drug Sentece Context

Table 1. Analysis of context sentence of icosapent gene in 9 abstracts.

pmid sentence
32984987 Our study revealed that only cilostazol has the most favorable binding interaction on Mpro (PDB ID: 6LU7) and cilostazol, iloprost, epoprostenol, prasugrel, and icosapent ethyl have a higher binding affinity on spike glycoprotein (S) (PDB ID: 6VYB) compared with recent anti-CoVID-19.
33009957 The studies reviewed include clinical trials on novel RNA interference-based lipid-lowering therapies AKCEA-APOCIII-LRx and vupanorsen (AKCEA-ANGPTL3-LRx); the EVAPORATE trial assessing the effects of icosapent ethyl on coronary plaque volume progression; the LoDoCo2 trial evaluating the efficacy of low-dose colchicine in cardiovascular disease risk reduction among patients with chronic coronary artery disease; as well as the EMPEROR-Reduced trial evaluating cardiovascular and renal outcomes with empagliflozin in patients with heart failure and reduced ejection fraction.
33033686 Icosapent ethyl (IPE) is an Omega-3 fatty acid derivative that has been shown to significantly reduce cardiovascular mortality and is used as an adjunct to statin therapy.
33061868 The REDUCE-IT trial demonstrated that icosapent ethyl, an ethyl ester of eicosapentaenoic acid (EPA), reduced cardiovascular events in an at-risk population by a substantial degree.
33311431 BACKGROUND Icosapent ethyl, a form of eicosapentaenoic acid with anti-inflammatory activity, has been approved as an adjunctive treatment with statins in patients with hypertriglyceridemia. […] Icosapent ethyl is currently undergoing clinical trials to determine its anti-inflammatory effects in patients with coronavirus disease 2019 (COVID-19). […] This report describes 3 intensive care unit (ICU) patients with moderate to severe COVID-19 pneumonia treated with icosapent ethyl as part of their supportive care who had favorable outcomes. […] All patients in these cases were treated with a course of 2 g of icosapent ethyl twice a day by nasogastric tube. […] CONCLUSIONS This report of 3 cases describes the use of icosapent ethyl as a component of supportive treatments in ICU patients with moderate to severe COVID-19 pneumonia. […] The outcomes of ongoing clinical trials are awaited to determine whether icosapent ethyl has anti-inflammatory effects in patients with SARS-CoV-2 infection and which patients might benefit from the use of this adjunctive treatment.
33365220 Icosapent Ethyl (IPE, Vascepa®) is an omega-3 fatty acid derivative that is indicated for the treatment of hypertriglyceridemia and has been shown to improve mortality from cardiovascular causes, likely through an anti-inflammatory mechanism.
33516752 The MITIGATE study aims to evaluate the real-world clinical effectiveness of pre-treatment with icosapent ethyl (IPE), compared with usual care, on laboratory-confirmed viral upper respiratory infection (URI)-related morbidity and mortality in adults with established atherosclerotic cardiovascular disease (ASCVD).